KMTS · Kestra Medical Technologies, Ltd.

Represents common shares earned with respect to an award of performance-based RSUs ("PSUs") granted on July 17, 2025, as determined based on the Issuer's achievement of specified performance goals. 100% of the PSUs vested on July 15, 2026.

Represents common shares earned with respect to an award of performance-based RSUs ("PSUs") granted on July 17, 2025, as determined based on the Issuer's achievement of specified performance goals. 100% of the PSUs vested on July 15, 2026.

The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.

The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $21.45 to $22.44. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.

The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $22.45 to $23.00. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.

The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $23.49 to $24.10. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

Represents common shares earned with respect to an award of performance-based RSUs ("PSUs") granted on July 17, 2025, as determined based on the Issuer's achievement of specified performance goals. 100% of the PSUs vested on July 15, 2026.

Represents common shares earned with respect to an award of performance-based RSUs ("PSUs") granted on July 17, 2025, as determined based on the Issuer's achievement of specified performance goals. 100% of the PSUs vested on July 15, 2026.

Represents common shares earned with respect to an award of performance-based RSUs ("PSUs") granted on July 17, 2025, as determined based on the Issuer's achievement of specified performance goals. 100% of the PSUs vested on July 15, 2026.

Shares purchased pursuant to the Kestra Medical Technologies, Ltd. 2025 Employee Stock Purchase Plan ("ESPP") in transactions that were exempt under Rule 16b-3, for the ESPP purchase period of January 1, 2026 through June 30, 2026.

In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 29, 2026.

Includes unvested RSUs.

Shares purchased pursuant to the Kestra Medical Technologies, Ltd. 2025 Employee Stock Purchase Plan ("ESPP") in transactions that were exempt under Rule 16b-3, for the ESPP purchase period of January 1, 2026 through June 30, 2026.

In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 29, 2026.

Includes unvested RSUs.

The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.

The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $20.5400 to $21.3900. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

Represents restricted stock units ("RSU") that entitle the Reporting Person to receive, at settlement, one common share of Kestra Medical Technologies, Ltd. Subject to the Reporting Person's continued service, the RSUs will vest over three years, with 1/3 vesting on each anniversary of June 3, 2026.

Represents restricted stock units ("RSU") that entitle the Reporting Person to receive, at settlement, one common share of Kestra Medical Technologies, Ltd. Subject to the Reporting Person's continued service, the RSUs will vest over three years, with 1/3 vesting on each anniversary of June 3, 2026.

Represents restricted stock units ("RSU") that entitle the Reporting Person to receive, at settlement, one common share of Kestra Medical Technologies, Ltd. Subject to the Reporting Person's continued service, the RSUs will vest over three years, with 1/3 vesting on each anniversary of June 3, 2026.

Represents restricted stock units ("RSU") that entitle the Reporting Person to receive, at settlement, one common share of Kestra Medical Technologies, Ltd. ("Common Share"). Subject to the Reporting Person's continued service, the RSUs will vest over three years, with 1/3 vesting on each anniversary of June 3, 2026.

Includes 5,837 Common Shares received from West Affum Holdings, L.P. in a pro rata distribution exempt pursuant to Rule 16a-9.

Represents restricted stock units ("RSU") that entitle the Reporting Person to receive, at settlement, one common share of Kestra Medical Technologies, Ltd. Subject to the Reporting Person's continued service, the RSUs will vest over three years, with 1/3 vesting on each anniversary of June 3, 2026.

The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.

The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $21.2433 to $21.6300. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.

The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $20.2200 to $20.2115. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.

The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $20.0000 to $20.2200. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $19.82 to $20.02. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.

The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $20.0000 to $20.7709. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

The reported securities represent restricted stock units ("RSUs") which each entitle the Reporting Person to receive one common share of the Issuer. The RSUs will vest on September 4, 2026, subject to the Reporting Person's continued service through such date.

The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.

The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $26.0200 to $26.9998. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.

The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $27.0771 to $27.1800. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.

The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $25.0150 to $26.0100. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.

The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $22.2800 to $23.1340. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2025.

The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $26.51 to $26.96. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

Includes 12,797 Common Shares received from West Affum Holdings, L.P. in a pro rata distribution exempt pursuant to Rule 16a-9.

The reported transaction occurred pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.

The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $26.390 to $26.9504. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

Includes 27,209 Common Shares received from West Affum Holdings, L.P. in a pro rata distribution exempt pursuant to Rule 16a-9.

The reported securities represent restricted stock units ("RSUs") which each entitle the Reporting Person to receive one common share of the Issuer. The RSUs will vest in three ratable installments on each of November 3, 2026, November 3, 2027 and November 3,2028, subject to the Reporting Person's continued service through such date.

The reported securities represent restricted stock units ("RSUs") which each entitle the Reporting Person to receive one common share of the Issuer. The RSUs will vest on September 4, 2026, subject to the Reporting Person's continued service through such date.

Includes 12,994 restricted common shares of the Issuer that were automatically converted in connection with the Issuer's initial public offering from Class A Common Units of West Affum Holdings, L.P. previously held by the Reporting Person which were originally granted on October 7, 2024. The restricted common shares vest into common shares of the Issuer. 4,331 restricted common shares will vest on October 7, 2025, 4,331 restricted common shares will vest on October 7, 2026 and 4,332 restricted common shares will vest on October 7, 2027.

The reported securities represent restricted stock units ("RSUs") which each entitle the Reporting Person to receive one common share of the Issuer. The RSUs will vest on September 4, 2026, subject to the Reporting Person's continued service through such date.

The reported securities in this row represent restricted stock units ("RSUs") which each entitle the Reporting Person to receive one common share of the Issuer. The RSUs will vest on September 4, 2026, subject to the Reporting Person's continued service through such date.

The reported securities represent restricted stock units ("RSUs") which each entitle the Reporting Person to receive one common share of the Issuer. The RSUs will vest on September 4, 2026, subject to the Reporting Person's continued service through such date.

The reported securities represent restricted stock units ("RSUs") which each entitle the Reporting Person to receive one common share of the Issuer. 2,212 RSUs will vest on June 4, 2026 and 10,908 RSUs will vest on September 4, 2026, in each case subject to the Reporting Person's continued service through such date.

The Reporting Person previously held restricted Class A Common Units of West Affum Holdings, L.P. granted on July 24, 2024, which were automatically converted into 12,994 restricted common shares of the Issuer in connection with the Issuer's initial public offering. The restricted common shares vest into common shares of the Issuer. 4,331 restricted common shares held by the Reporting Person vested on July 24, 2025. Of the remaining restricted common shares held by the Reporting Person, 4,331 restricted common shares will vest on July 24, 2026 and 4,332 restricted common shares will vest on July 24, 2027.

Represents restricted stock units ("RSU") that entitle the Reporting Person to receive, at settlement, one common share of Kestra Medical Technologies, Ltd. Subject to the Reporting Person's continued service, the RSUs will vest 7,353 on July 17, 2026, 7,353 on July 17, 2027 and 7,354 on July 17, 2028.

Represents restricted stock units ("RSU") that entitle the Reporting Person to receive, at settlement, one common share of Kestra Medical Technologies, Ltd. Subject to the Reporting Person's continued service, the RSUs will vest 29,333 on July 17, 2026, 29,333 on July 17, 2027 and 29,334 on July 17, 2028.

The reported securities were purchased in connection with the Issuer's initial public offering reserved share program and were inadvertently omitted from the Reporting Person's prior filings.

The reported securities were purchased in connection with the Issuer's initial public offering reserved share program and were inadvertently omitted from the Reporting Person's prior filings.

The reported securities in this row were purchased in connection with the Issuer's initial public offering reserved share program and were inadvertently omitted from the Reporting Person's prior filings.